Chuangyebang was informed that recently, Suzhou U-Synbio Technology Co., Ltd. (hereinafter referred to as “U-Synbio”) completed an angel round of financing of tens of millions, which was jointly invested by Inno Angel, Suzhou Industrial Park Science and Technology Innovation Fund and Shuimu Tsinghua . This round of financing is mainly used for the company’s team development, laboratory construction, development of a series of pipeline products, as well as the optimization and upgrading of the core technology platform and external cooperation.
U-Synbio was established in 2021. The founder of the company, Dr. Chen Jingyu, graduated from Tsinghua University and has work experience in the Western Regional Research Center of the USDA and the University of California, Davis. U-Synbio is a technology-driven synthetic biology company. Medical Applied Technologies Inc. In 2021, U-Synbio won the honor of Suzhou Industrial Park Technology Leading Talent Project. In the next few years, Uxin Hesheng will use synthetic biology technology to improve the living biological drug technology platform, and focus on the development of a series of pipeline products for rare metabolic diseases, so as to create greater value for human health.
Live biotherapeutic products (LBPs) are living organisms designed and developed for the treatment, cure or prevention of human disease. LBP is an entirely new field of medicine. Using the tools of synthetic biology, chassis bacteria can be engineered to sense and respond to environmental signals to consume harmful compounds and deliver therapeutics.
Synthetic biology is a discipline that combines biological science and engineering to design and construct biological genomes and systems with new biological functions. Synthetic biology has brought about the third biotechnology revolution and is one of the disruptive technologies leading the twenty-first century. Gene editing living biological drug LBP is an important application of synthetic biology in medicine, and one of the research hotspots in the global scientific community.
Dr. Chen Jingyu expressed his heartfelt thanks to the investors for their recognition and support: “The rapid development of synthetic biology provides the possibility to realize the application of biotechnology in multiple fields. The founding team of Uxin Hesheng has been deeply involved in the field of synthetic biology technology for many years and is familiar with innovative drugs. Research and development needs. With the goal of LBP innovative drug development, Uxin Hesheng has created a LBP synthetic biology transformation platform to provide new solutions for the treatment of various diseases. In the future, Uxin Hesheng will continue the past and forge ahead, rapidly promote pipeline product research and development and clinical application, Continue to demonstrate the infinite potential of synthetic biology to provide efficient and high-quality treatment solutions for precision medicine and personalized medical needs.”
Zhu Xiaocheng, a partner of the investor Inno Angel, said: Synthetic biology has been widely used in the production of natural products and the research and development of new materials, but it is still blank in the field of clinical treatment. The development of LBP drugs in combination with probiotics provides a new way to treat metabolic diseases. Yingnuo is optimistic about the application of synthetic biology technology, and has deployed a number of cutting-edge technology companies. Dr. Chen Jingyu, the founder of Uxin, and his R&D team have deep technical reserves in the direction of LBP. In the next 2-3 years, there will be multiple pipelines that will be brought to the clinic to meet the treatment needs of patients and escort public health!
Zhao Yuxu, project leader of the Investor Park Science and Technology Innovation Fund, said: The project is based on synthetic biology technology to develop LBP drugs, which can effectively solve the problem of genetic metabolic diseases. It is a platform company of biotechnology and has great value-added potential. The core team members have also been committed to the research and development of synthetic biology and strains for many years, and the strong alliance with people with rich clinical and entrepreneurial experience is believed to have the ability to quickly promote the product to the market. This investment in Uxin Hesheng is also for the purpose of further layout and improvement of the biopharmaceutical industry ecosystem in Suzhou Industrial Park, and to enhance regional innovation capabilities.
Li Zhu, partner of the investor Shuimu Tsinghua Alumni Fund, said: Dr. Chen Jingyu graduated from Tsinghua University and studied under Professor Chen Guoqiang, an expert in synthetic biology, and has a deep understanding of synthetic biology technology. The LBP drugs developed by the team have shown excellent prospects in the treatment of many rare diseases and metabolic diseases. Shuimu Tsinghua Fund is optimistic that under the leadership of alumni Professor Chen, Uxin will accelerate the early launch of various LBP drugs and enrich clinical treatment methods.
media coverage
The investment community Yiou Venture State
Related events
- Financing丨“Uxin Hesheng” completed the angel round of financing, focusing on the development of living biological drugs in synthetic biology2022-05-20
- Uxin : Revenue in the second quarter was 346 million yuan, a year-on-year increase of 352.7% 2021-12-15
- Uxin releases Q1 financial report for fiscal year 2022, with transaction volume up 75% month- on- month 2021-09-24
- Uxin Announces the Official Signing of a US$315 Million Financing Agreement2021-06-15
- Uxin ‘s 2021 fiscal year Q3 financial report: total revenue of 323 million yuan, gross profit margin turned positive2021-04-28
This article is reprinted from: https://readhub.cn/topic/8gacDQ4GGkj
This site is for inclusion only, and the copyright belongs to the original author.